Comparison of recombinant human erythropoietin and darbepoetin alpha in children

Can C., Emre S., Bilge I., Yilmaz A., Sirin A.

PEDIATRICS INTERNATIONAL, vol.55, no.3, pp.296-299, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1111/ped.12085
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.296-299
  • Keywords: anemia, child, chronic kidney disease, darbepoetin alpha, recombinant human erythropoietin, STAGE RENAL-FAILURE, STIMULATING PROTEIN, PEDIATRIC-PATIENTS, DE-NOVO, ANEMIA, EVERY
  • Istanbul University Affiliated: Yes


Background The aim was to compare the clinical efficacy of recombinant human erythropoietin (rHuEPO) and darbepoetin alpha (DA) in the treatment of anemia in children with chronic kidney disease (CKD). Method Thirty-four (13 female, 21 male) CKD patients were enrolled in the study. Mean age was 11.42 +/- 4.05 years. Nine patients were on hemodialysis, 18 were on peritoneal dialysis and seven patients were in CKD stage 4. Results Seventeen patients received rHuEPO and the remaining 17 patients received DA. Hemoglobin (Hb) was not significantly different between the two groups during monthly follow up and at the end of 6 months (P > 0.05), but there was a significant increase within each group at the end of 6 months (P = 0.01 for rHuEPO; P = 0.02 for DA). Hb was not different between the patients on and not on dialysis in both groups at the end of the study (P > 0.05). The efficacy of the s.c. and i.v. routes was similar within each group (P > 0.05). Systolic hypertension was observed in only one patient in the DA group, no other adverse effect was observed in either groups. Conclusion DA is a reasonable alternative to rHuEPO in the treatment of anemia in pediatric CKD patients, due to its clinical efficacy, convenience of use, patient compliance and tolerability.